Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023
November 02, 2023 at 04:06 pm EDT
Share
Penumbra, Inc. provided earnings guidance for the full year 2023. For the fourth quarter of 2023, the company expects total company revenue growth to accelerate to 28% to 31% year over year, which correlates to the midpoint of annual guidance range of $1.05 billion to $1.07 billion for full year 2023.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.